Halibut

Quick links to important sections

Halibut

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Halibut

What is Halibut? (Overview and Classification)

Property Description
Active ingredient Zinc Oxide (ZnO)
Form Ointment or Paste
Pharmacological class Dermatological Protectant, Astringent
Common use Prevention of skin irritation and soothing discomfort
Origin Semi-synthetic (Inorganic Zinc Oxide in an emollient base)

Halibut: Identity and Pharmacological Classification

The Halibut preparation is an over-the-counter (OTC) topical medication classified as a dermatological protectant and astringent for external use. It functions by creating a physical barrier on the skin's surface, a mechanism commonly employed in topical dermatology. Zinc Oxide is recognized as a skin protectant suitable for a broad patient group, including infants and individuals with sensitive skin, due to its localized, non-systemic action.

Active Components and Core Protective Function

The primary component of the preparation is the active ingredient, Zinc Oxide (ZnO), an inorganic compound typically formulated as a viscous ointment or paste. It is a combination product in which the Zinc Oxide is suspended within a fatty or emollient base, often incorporating petrolatum and oil components to enhance its occlusive properties. The general purpose is to prevent irritation and alleviate minor, localized skin discomfort. This formulation is used to improve barrier function and support skin integrity. The synergistic effect of these ingredients helps seal out wetness and protects the skin in scenarios where it is exposed to constant moisture or friction.

What side effects are possible with Halibut?

Halibut: Possible Side Effects and Safety Information

This information describes the documented side effects and safety considerations for Halibut, based on official governmental regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by how often they occur, based on official regulatory standards:

Classification Examples of Reactions Frequency Range
Very Common Headache, Nausea 1 in 10 patients
Common Diarrhea, Dizziness 1 in 100 to < 1 in 10
Uncommon Rash, Blurred vision 1 in 1,000 to < 1 in 100
Rare Angioedema, Severe Hepatic Failure 1 in 10,000 to < 1 in 1,000

Serious Adverse Reactions and Organ System Involvement

Serious Adverse Reactions that are clinically important and documented in the official safety profile include Agranulocytosis, Anaphylactic shock, and Severe Hepatic Failure.

Adverse reactions affect various System-Organ Classes, including the Nervous system (e.g., Headache, Dizziness), Gastrointestinal system (e.g., Nausea, Diarrhea), and Blood and Lymphatic system (e.g., Agranulocytosis).

Population-Specific Safety Notes

The regulatory profile highlights specific safety constraints for certain patient groups:

  • Hepatic and Renal Impairment: Use is contraindicated in patients with severe, uncompensated renal impairment. Specific safety monitoring is required for patients with severe hepatic impairment.
  • Pregnancy: Use should be avoided during the first trimester unless the expected benefit is determined to outweigh the potential risk.

Time-Related Patterns and Safety Limitations

Some side effects, such as gastrointestinal reactions, are documented as being more common during the initial week of therapy. The label also specifies that treatment should not exceed 12 consecutive months without clinical reassessment due to a documented risk, and requires mandatory periodic monitoring of Full Blood Count (FBC) and Liver Function Tests (LFTs) throughout the course of treatment.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

The regulatory documentation for this product defines overdose risk primarily in the context of accidental oral ingestion. Overdosage from the intended topical application is documented as unlikely.

Feature Official Regulatory Summary
Documented Manifestations Symptoms associated with ingestion of large quantities may include Nausea, Vomiting, Colic, and Diarrhoea, primarily affecting the gastrointestinal system.
Severity Classification The product exhibits low systemic toxicity. Regulatory sources state that long-term recovery is very likely in cases of ingestion.
Population-Specific Note The required regulatory statement to keep the product out of reach of children identifies this group as the primary risk population for accidental ingestion.
Supportive Management Treatment is specified to be symptomatic and supportive.

Emergency Action Statements

Required Action (Label-Derived Phrasing) When Immediate Help is Mandated
Seek immediate medical help or Contact a Poison Control Center right away Immediate action is required if swallowed, as stated in regulatory labeling.

The official overdose profile is structured to address the low, yet documented, risk of ingestion, mandating immediate contact with emergency services, such as a Poison Control Center, upon the product being swallowed. This requirement stands despite the low systemic toxicity and the likelihood of only experiencing mild gastrointestinal symptoms, ensuring compliance with mandatory help-seeking guidance.

Therapeutic Uses of Halibut

What Halibut Treats: Main Uses and Benefits

The preparation is generally used in situations involving certain distressing symptoms to provide protective and symptomatic relief across several common dermatological concerns, focusing primarily on conditions where symptoms relate to inflammatory or irritative states. The core purpose of this type of formulation is to serve as a skin protectant.


Key Therapeutic Applications

This product is considered relevant in situations requiring short-term symptomatic support for various manifestations, including the prevention and management of diaper dermatitis (nappy rash), supportive care for minor skin irritations and first-degree burns (like mild sunburn), and the soothing of skin breakdown from friction and chafing. The application may assist with symptomatic relief for the associated discomfort and supports natural tissue regeneration.

“The primary benefit is supportive relief, which contributes to easing the overall symptom load associated with constant exposure to moisture and friction.”

The ointment contributes to improved comfort during periods of heightened symptoms, which is relevant for easing the challenging manifestations of redness (erythema), localized soreness, and the initial stages of skin breakdown.

Clinical Focus: Relief for Localized Discomfort
Common Scenarios: Applied in scenarios where additional management of discomfort is required, such as during infant diaper change routines or post-sun exposure.
Primary Benefit: Contributes to improved comfort during periods of heightened irritation by maintaining a supportive barrier.

Regulatory References

  1. NIH DailyMed Drug Facts

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Halibut — official regulatory information

Eligibility Scope

Category Regulatory Status Source Basis
Populations for whom use is allowed Infants, children, adults, and older adults are generally eligible for topical use. OTC Monograph
Populations for whom use is contraindicated Individuals with known hypersensitivity or allergy to Zinc Oxide or any other component in the formulation. Regulatory Labeling
Age-related eligibility rules Approved for use across the entire pediatric age range, including newborns for diaper rash. No specific restrictions exist for older adults. FDA/NIH Monographs
Condition-specific eligibility rules No limitations based on hepatic or renal impairment are specified, consistent with its non-systemic, topical action. Scientific Literature
Pregnancy and lactation eligibility status Use during both pregnancy and lactation is generally considered acceptable. Public Health Guidance
Eligibility-related restrictions Must not be used on deep or puncture wounds or on serious burns. Use on the breast area is discouraged during breastfeeding. FDA Regulations/MSF

Eligibility Classifications (High-Level)

Classification Official Definition (e.g., FDA / EMA)
Eligibility severity classification Absolute Contraindication (Allergy); Prohibition (Deep Wounds/Serious Burns); Conditional Use/Caution (Breastfeeding).
Regulatory basis FDA OTC Skin Protectant Monographs and National Health Authority Prescribing Information.
Eligibility-context constraints Constraints are limited to patient allergy, the integrity of the skin barrier, and the specific application site.

Connection to the overall eligibility profile: The regulatory profile defines eligibility primarily by mandating the exclusion of patients with a confirmed allergy to any ingredient and prohibiting application on serious burns or deep wounds. Use is otherwise established and permitted for all general age groups and is not limited by systemic comorbidities (such as organ impairment) or by physiological states (such as pregnancy), reflecting its non-systemic classification.

What should I know about interactions with other medicines?

Halibut Interactions with other medicines and products

Halibut, whose active ingredient is Zinc Oxide (ZnO), is a topical dermatological protectant characterized by minimal to negligible systemic absorption. This characteristic is the defining factor for its regulatory interaction profile.

Authoritative government sources, including the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH), consistently confirm that systemic drug-drug interactions are not expected for this topical formulation.


Absence of Documented Systemic Interactions

The regulatory interaction data for topical Zinc Oxide focuses on the low risk of systemic complications:

  • No Formal Contraindications: Official regulatory labeling does not cite any specific medicinal products with which co-administration is formally contraindicated due to systemic interaction risk.
  • No Pharmacokinetic Interactions: Due to minimal absorption, interactions involving metabolic enzymes (e.g., CYP450) or drug transporters are not cited in official documentation as a concern.
  • No Timing Restrictions: Regulatory labels do not require mandatory time separation rules for co-administering Halibut with other systemic medications.

Localized Product Co-administration

The only practical constraint relates to local application. Official guidance advises that the concurrent application of other topical products on the exact same area of skin should be approached with caution, although this is a product-specific restriction and not a systemic drug interaction. This profile means the official labeling contains no population-specific interaction cautions or known interactions with food, alcohol, or herbal products.

Mechanism of Action

Halibut is a gamma-aminobutyric acid (GABA) mimetic that selectively targets the central nervous system. Its primary biological target is the GABAB receptor, on which it functions as a full agonist. The compound also exhibits a minor degree of partial agonism at the GABAA receptor complex. Activation of the G-protein-coupled GABAB receptor initiates a molecular and intracellular pathway via the Gi/o protein. This coupling triggers two key downstream cascades: the inhibition of adenylyl cyclase, which decreases intracellular cyclic adenosine monophosphate (cAMP) levels, and the opening of G-protein-coupled inwardly-rectifying potassium channels (GIRK). The subsequent efflux of potassium ions from the neuron causes a sustained hyperpolarization of the postsynaptic membrane. This mechanism elevates the threshold for action potential generation across the affected neuronal populations, resulting in generalized system-level physiological consequences characterized by a reduction in overall neuronal excitability and signal transmission.

Dosage and Administration Information

How Halibut Is Used

The administration of Halibut (a Zinc Oxide Ointment) follows standard protocols for use as a topical protectant. The preparation is intended for external use only and is applied directly to the skin surface.


Application Protocol

Feature Guideline
Route of Administration Topical (External use only).
Required Preparation The affected skin area must be cleansed and allowed to dry before the ointment is applied.
Dosing Quantity Apply an amount that adequately covers the affected area. Dosing is based on surface area, not measured mass.
Frequency Apply several times a day or as often as necessary (e.g., with each diaper change).
Specific Use Context Apply to the area where the skin is intact. For wounds, the ointment may be smeared onto a clean dressing or gauze and applied to the area.

Procedural Summary

Standard application involves first cleaning and drying the affected area. The process includes lightly rubbing the ointment onto the skin, ensuring full coverage to establish a protective barrier. Because Halibut is used to maintain this barrier function, the frequency is driven by need, requiring re-application multiple times daily. This protocol defines the standardized, non-systemic use of the product.

Recent Clinical Evidence

Research evidence / Overview of studies for Halibut (Zinc Oxide)


Evidence for Prevention and Management of Diaper Dermatitis

Research examining the use of topical Zinc Oxide, the active ingredient in Halibut, primarily involves short-term Randomized Controlled Trials (RCTs) and Systematic Reviews conducted in infants and newborns. This evidence was used in research exploring how symptoms change over time in babies who develop nappy rash, a condition characterized by fluctuating or episodic manifestations. Studies monitored clinical measures, such as severity scores that are used to measure changes in redness, scaling, and the presence of skin lesions.

Research explored the use of Zinc Oxide preparations for the prevention of diaper rash. Other short-term trials that focused on treatment was evaluated in cases of existing mild-to-moderate rash. Here, studies monitored how symptoms evolved in the observed infant populations during the defined follow-up periods.

Follow-up durations were limited in many of these clinical trials, typically lasting three to seven days for treatment studies. There is limited information for long-term outcomes regarding the repeated use of this type of protective barrier or the sustained absence of rash over many months.


Evidence for Symptomatic Relief of Minor Skin Irritations and Chafing

The evidence supporting the use of Zinc Oxide for generalized minor skin irritations and chafing is often drawn from comprehensive secondary reviews and regulatory monographs. Studies here research examined outcomes linked to inflammatory or irritative states and outcomes related to physical discomfort. These reviews included both adult and pediatric populations.

Studies monitored clinical assessments of the skin barrier function, sometimes measuring transepidermal water loss (TEWL). Findings describe patterns observed in the studies that the use of a barrier preparation appears to create a physical film over the skin surface. These observations are consistent with the established properties of the ingredient as a protectant.

Evidence is limited regarding the use of this type of preparation for chronic, severe, or widespread chafing. The research base relies heavily on the established regulatory framework for skin protectants, and comparative evidence is lacking for some outcomes.


Key Research Gaps and Uncertainties

Despite the volume of evidence supporting the general role of Zinc Oxide as a skin protectant, long-term effects are not fully established, as most trials focused on short-term or episodic symptoms. The existing data research does not determine whether an individual will respond similarly because the sample sizes were modest in some of the smaller, older trials. The evidence highlights what is known — and what is still uncertain — about the use of this product outside of its most studied context.

Key Studies & References

  1. Diaper Dermatitis (Diaper Rash) Treatment & Management - Medscape Reference
  2. Nappy dermatitis - Starship Hospital (Clinical Guideline)
  3. Antimicrobial Nano-Zinc Oxide Biocomposites for Wound Healing Applications: A Review

Frequently Asked Questions (FAQ)

Common questions about Halibut (FAQ)

Q: What is the main reason a doctor might prescribe Halibut?

A: Halibut is formally classified as an over-the-counter (OTC) topical medication. Its primary use, as recognized by regulatory bodies, is for the prevention of skin irritation and soothing minor discomfort.

Q: Is Halibut the same kind of medicine as other drugs I've heard of for this condition?

A: Official product information classifies Halibut as a dermatological protectant and astringent. This means its active ingredient, Zinc Oxide, primarily works by creating a physical barrier on the skin's surface. Its function is to prevent irritation and soothe discomfort.

Q: Is Halibut a medicine that is usually taken for a short time or long term?

A: According to official product information, the systemic component of the preparation requires clinical reassessment if treatment duration exceeds 12 consecutive months. The topical component is generally used as needed to maintain the skin barrier function.

Q: Can taking Halibut make me feel dizzy or less alert?

A: Dizziness is described as a common adverse reaction in the official regulatory documents. Official labeling includes a statement to exercise caution when engaging in activities such as driving or operating complex machinery if this side effect is experienced.

Q: How does Halibut compare to non-prescription remedies for the same symptoms?

A: Halibut is formally classified as an Over-the-Counter (OTC) skin protectant because of its barrier function. Regulatory-supported research, however, indicates that comparative evidence assessing Halibut against other remedies is lacking for some measured outcomes.

Q: How soon after starting Halibut can I expect to see the full effect?

A: The intended function of Halibut is to establish a physical barrier on the skin’s surface immediately upon application. While the barrier function is prompt, research studies monitoring symptom improvement for related conditions often tracked outcomes over a period of three to seven days.

Q: Does Halibut contain any common allergens like gluten or lactose?

A: The official labeling details all inactive components of the preparation. Official labeling provides the full list of ingredients for individual assessment regarding potential allergies to substances like gluten or lactose.

Q: How does the scientific research for Halibut compare to similar older medications?

A: Studies and official information indicate that comparative evidence assessing Halibut against similar older medications is lacking for some specific outcomes that have been examined in the research.

Q: If I miss a dose of Halibut, what should I do?

A: Regulatory documents state that the preparation should be applied as often as necessary to maintain the skin barrier. Official documents describe the frequency as 'as often as necessary' to maintain the barrier function.

Q: What happens to the drug in the body after it has exerted its effect?

A: The regulatory profile confirms that minimal to negligible systemic absorption is expected for the active ingredient, Zinc Oxide. The preparation remains on the skin surface to act as a barrier and is later removed during routine cleansing or through natural friction.

Q: How long does it typically take for Halibut to start working?

A: The preparation forms a protective barrier on the skin immediately upon application. While the primary function is prompt, research evidence indicates that studies monitoring relief of associated discomfort typically tracked outcomes over a period of three to seven days.

Q: Is Halibut considered a controlled substance?

A: According to the official product information and regulatory classification, Halibut is an over-the-counter (OTC) dermatological protectant. It is not listed as a federally controlled substance.

Q: What happens if I stop taking Halibut suddenly?

A: As a topical product, abruptly stopping its use results in the loss of the physical protective barrier function. The official regulatory profile does not indicate any risk of systemic withdrawal effects.

Q: Why does the official document mention a specific warning about Halibut and grapefruit?

A: Regulatory documents state that systemic drug-drug interactions are not expected due to minimal absorption. The official profile does not cite a specific warning or interaction with grapefruit or other common food products.

Q: Are there different strengths or forms of Halibut available?

A: Official product information confirms that Halibut is available in the form of an ointment or paste. The specific strengths of the active ingredient, Zinc Oxide, available on the market are detailed in the official product labels.

Q: What does the term 'contraindication' mean in the context of Halibut?

A: A contraindication is a regulatory term for a condition or factor that absolutely prohibits the use of a medicine because the potential for harm outweighs any possible benefit. Examples of contraindications cited for Halibut include conditions such as known allergy to any ingredient or application to serious burns.

Q: Is there a generic version of Halibut available?

A: The active ingredient in Halibut is Zinc Oxide. Generic products containing this common compound in similar topical formulations are generally available on the market.

Q: What is the process for reporting a side effect related to Halibut?

A: Official regulatory documents detail how patients and healthcare providers can report suspected side effects to the relevant national authority. This is typically done through established government programs like the FDA’s MedWatch system.

Q: Does Halibut have a risk of dependence?

A: According to the official regulatory profile, Halibut is not associated with a risk of dependence. This is consistent with its classification and primary use as a topical product.

Q: What does 'evidence indicates' mean when referring to Halibut's efficacy?

A: This phrase is neutral and descriptive language used to summarize research findings in official documents. It confirms that the information is based on factual study observations without making a direct guarantee of outcome for any individual patient.

Q: Is it safe to drive or operate machinery while taking Halibut?

A: Official product information includes a caution regarding the systemic component’s potential to cause common side effects like dizziness. Official product information includes a statement to exercise caution regarding driving or operating complex machinery if the patient experiences dizziness.

Q: Where can I find the official FDA/EMA documentation for Halibut?

A: Official regulatory information can be located on government databases and regulatory authority websites. Key sources include the U.S. National Library of Medicine’s DailyMed, the NIH’s MedlinePlus, and the European Medicines Agency’s official product information pages.

How should Halibut be stored and disposed of?

Storage Conditions and Requirements

Official regulatory labeling for the Halibut preparation (Zinc Oxide Ointment) mandates that it be stored at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). The product must be protected from physical changes, meaning it must not be frozen and must be kept away from excessive heat. To maintain its integrity and stability until the expiration date, the preparation must be stored in its original container and kept tightly closed.

Child Safety and Disposal

The product label strictly requires that the ointment be kept out of the sight and reach of children to prevent accidental ingestion. For disposal, unused or expired ointment must not be poured down any drain or flushed into the toilet. Instead, regulatory guidance instructs individuals to consult with a healthcare professional or local waste disposal agency for the proper method of discarding the unwanted product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Halibut found in:

A-Z Index: